Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
24 Luglio 2023 - 10:01PM
Business Wire
Arcturus to present at the Canaccord Genuity
43rd Annual Growth Conference, August 9, 2023
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that the Company will release its
financial results for the quarter and six months ended June 30,
2023 after the market close on Monday, August 7th and will also
host a conference call and webcast at 4:30 p.m. Eastern Time on
August 7th, 2023.
The Company also announced it will present at the Canaccord
Genuity 43rd Annual Growth Conference in Boston, on August 9, 2023,
at 9:30 a.m. Eastern Time.
Arcturus Therapeutics Second Quarter 2023 Earnings Conference
Call
- Monday, August 7, 2023 @ 4:30 p.m. ET
- Domestic: 1-877-407-0784
- International: 1-201-689-8560
- Conference ID: 13738872
- Webcast: Link
Canaccord Genuity 43rd Annual Growth Conference
- Wednesday, August 9, 2023 (9:30 a.m. ET)
A webcast and replay of the presentation will be available on
the “Investor Relations/Events” section of the Company’s website
at: https://ir.arcturusrx.com/investor-calendar
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ pipeline includes RNA
therapeutic candidates to potentially treat ornithine
transcarbamylase deficiency and cystic fibrosis, along with its
partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and
influenza. Arcturus’ versatile RNA therapeutics platforms can be
applied toward multiple types of nucleic acid medicines including
messenger RNA, small interfering RNA, circular RNA, antisense RNA,
self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’
technologies are covered by its extensive patent portfolio (patents
and patent applications issued in the U.S., Europe, Japan, China,
and other countries). For more information, visit
www.ArcturusRx.com. In addition, please connect with us on Twitter
and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724923903/en/
IR and Media Contacts Arcturus Therapeutics Neda
Safarzadeh VP, Head of IR/PR/Marketing IR@arcturusrx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Grafico Azioni Arcturus Therapeutics (NASDAQ:ARCT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Arcturus Therapeutics (NASDAQ:ARCT)
Storico
Da Giu 2023 a Giu 2024